A newly launched clinical trial in the United Kingdom aims to cut the time required to evaluate potential Alzheimer’s disease medications by more than half. Known as Ad-Smart—short for Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial—the initiative is led by the UK Dementia Research Institute and Alzheimer’s Research UK, with financial support from the British government and other research funders, according to The Independent.
Rather than testing a single experimental compound in isolation over several years, the study uses an adaptive platform design to evaluate multiple medications simultaneously. The trial is beginning with two established, repurposed medications: atomoxetine, commonly prescribed for attention deficit hyperactivity disorder (ADHD), and metformin, a standard frontline medication for type 2 diabetes. Researchers have already begun enrolling initial participants through National Health Service (NHS) trusts to examine whether these accessible therapies can slow cognitive decline, preserve memory, and help patients maintain daily independence.
How Adaptive Trials Change Drug Testing
Traditional clinical trials for neurodegenerative conditions are notoriously slow and expensive. Typically, researchers must assemble a completely new trial infrastructure, recruit a fresh cohort of patients, and establish separate control groups for each individual drug candidate. If a medication fails to show benefit, the entire framework is dismantled, and scientists must start from scratch for the next study.
The Ad-Smart study addresses this bottleneck through an adaptive, multi-arm framework. Under this structure, multiple treatments are tested side by side against a shared placebo group. Throughout the study, participants undergo regular brain scans and blood tests to monitor biological markers of disease progression alongside assessments of their thinking and memory abilities.
This flexible protocol allows investigators to drop ineffective drugs early and introduce new candidate therapies—including both repurposed medications and newly developed Alzheimer's compounds—into the active trial without rebuilding the operational infrastructure. Chief investigator Professor Paresh Malhotra of the UK Dementia Research Institute is overseeing the effort, which project leaders say could cut the evaluation timeline for prospective Alzheimer's therapies by more than 50 percent.
Why ADHD and Diabetes Medications Are Being Tested
Repurposing existing medications offers a major practical advantage in clinical research. Because drugs like atomoxetine and metformin have already been prescribed to millions of patients worldwide for their primary conditions, their safety profiles, side effects, and manufacturing standards are thoroughly documented. If clinical testing confirms they benefit brain health, these medications can be approved and distributed to neurology patients much faster than brand-new chemical entities.
According to researchers referenced by The Independent, both initial drugs were selected based on biological evidence linking their mechanisms of action to Alzheimer’s pathology:
- Atomoxetine: Approved to treat ADHD, this medication increases levels of noradrenaline, an important chemical messenger in the brain. Existing scientific evidence indicates that atomoxetine targets biological mechanisms linked to ongoing neurodegeneration in Alzheimer’s patients.
- Metformin: Widely used to manage blood sugar in type 2 diabetes, metformin improves insulin sensitivity and lowers systemic inflammation. Scientists note that the medication shows promise across specific cellular pathways involved in brain aging and metabolic damage.
By evaluating whether these medications ease symptoms like poor memory and cognitive difficulties, the research team hopes to identify accessible treatments that protect overall quality of life.
Personal Loss Drives Public Support
The launch of the Ad-Smart initiative carries personal significance for UK Prime Minister Andy Burnham, who publicly endorsed the trial following the death of his father, Roy Burnham, in September. A former telephone engineer, the elder Burnham lived in a care home during the advanced stages of dementia and remained unaware of his son's political role prior to his passing.
"I know how it feels to lose a loved one to dementia and have seen first-hand the devastating impact this illness has on families," Burnham stated, according to The Independent. "That’s why I’m proud to see this trial being launched in the UK, so that cutting-edge treatments can reach patients here as soon as possible."
Burnham noted that he has made dementia research a national priority, expressing a commitment to helping the country lead in medical discoveries that directly improve patient outcomes. Alzheimer’s disease is the most common form of dementia, affecting approximately 600,000 people across the United Kingdom and millions more in the United States and worldwide.
What Patients and Families Should Expect Next
Recruitment for the Ad-Smart study is currently underway. The first participants have enrolled at the Cambridgeshire and Peterborough NHS Foundation Trust and the Surrey and Borders Partnership NHS Foundation Trust. Additional clinical sites are launching at Imperial College Healthcare in London, as well as in Edinburgh and Southampton.
Over the next 18 months, trial organizers plan to open up to 20 NHS testing locations to recruit more than 1,000 participants living with Alzheimer’s disease. Researchers expect to reach definitive clinical conclusions regarding the first wave of tested medications—atomoxetine and metformin—by 2030.
While the launch of an accelerated trial framework represents a constructive step forward for neurological research, health experts emphasize that these therapies remain strictly experimental for dementia. Patients and caregivers should never attempt to use ADHD or diabetes medications off-label to treat memory loss outside of a monitored clinical study. Individuals interested in learning more about dementia management or clinical trial eligibility should consult a board-certified neurologist or primary care physician.
